On 22 February 2019, the Global Fund Board approved one multi-country grant, one matching funds request and one set of interventions on the Unfunded Quality Demand (UQD) Register –– worth a total of $16.0 million. The Board was acting on the recommendations of the Technical Review Panel (TRP) and the Grant Approvals Committee (GAC). This was the 17th batch of approvals from the 2017–2019 allocations.
South Africa confronts HIV prevention challenge for adolescent girls and young women with new Global Fund grant
South Africa, home to the largest national HIV epidemic globally, is getting ready to begin implementation of a new Global Fund grant for the period 1 April 2019 to 31 March 2022 in the amount of $353.3 million. The funding request was submitted during Window 6 (on 6 August 2018) and was reviewed by the Technical Review Panel (TRP) in September 2018.
The TRP recommended South Africa’s funding request.
On 31 January 2019, the Global Fund Board approved three country grants worth $13.4 million. It also approved two multicountry grants valued at $22.5 million. The Board was acting on the recommendations of the Technical Review Panel (TRP) and the Grant Approvals Committee (GAC). See Tables 1 and 2 for listings of the country and multi-country grants.
The Kenya Medical Supplies Authority (KEMSA) successfully procures and distributes government, Global Fund, and other donor-funded commodities. Prices obtained by KEMSA are competitive compared to prices obtained by the Global Fund’s Pooled Procurement Mechanism (PPM), stock-outs of health commodities occur rarely, if ever, commodities are delivered in a timely fashion, and inventory is properly managed at all stages of the supply chain.
OIG investigation reveals deficiencies in Global Fund processes for procurement of HIV rapid test kits in eight countries
A proactive investigation undertaken by the Office of the Inspector General (OIG) has identified some deficiencies in the Global Fund’s processes for procuring HIV rapid diagnostic test (RDT) kits. A report on the investigation was released on 31 May 2018.
In the beginning, there was performance-based funding. It was the outcomes-based mechanism of choice for the Global Fund and forms the foundation on which the Global Fund’s grant architecture was built. The idea was simple. Release funding in tranches, whereby recipients were required to reach specific targets before the rest of the grant would be disbursed.
In what has been hailed as a “breakthrough” and a “game changer,” a pricing agreement between the Bill and Melinda Gates Foundation and two generic drug companies will result in significant savings in the cost of antiretrovirals (ARVs). As a result of the agreement, starting in 2018 a state-of-the-art fixed dose combination ARV regimen will be available in 92 developing nations at a maximum cost of $75 per patient per year.
On 19 July 2017, the Global Fund published an audit report by the Office of the Inspector General (OIG) on grants to the Republic of South Africa. The country is part of the Fund’s High Impact Africa 1 portfolio and has $312 million in signed grants for the implementation period April 2016 to March 2019.
The Global Fund, one of the main purchasers of generic antiretroviral (ARV) medicines for HIV patients in low- and middle-income countries, has dismissed concerns that the limited number of manufacturers tapped to supply these drugs could result in immediate or future shortages. Fund officials said systems are in place to forecast demand, deal with any supply disruptions and increase production to meet future need.